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CD200 is a widely expressed transmembrane glycoprotein that transmits an inhibitory signal after ligation of the
structurally homologous CD200-receptor-1 (CD200R1). Recently, we showed that CD200 is expressed on keratin-
ocytes and plays a role in protecting hair follicles from autoimmune attack. Here, we report the characterization of
cell surface and mRNA expression of CD200R1 by cells of the murine epidermis. In addition, we report mRNA
expression for other members of the CD200R-family (R2–R4) by quantitative real-time RT-PCR. Variable levels of
CD200R1, R2, R3, and R4 mRNA were detected in bulk epidermal cell suspensions. Freshly isolated Langerhans
cells (LC) preferentially expressed CD200R1. Consistent with an inhibitory role for CD200:CD200R1 interaction, LC
obtained from mice deﬁcient in CD200 (CD200/) were in a heightened state of activation as compared with wild-
type (CD200þ /þ ) cells. Freshly isolated dendritic epidermal T cells (DETC) expressed low levels of CD200R1, R2,
and R3 mRNA, but they preferentially increased cell surface and mRNA expression of CD200R1 upon activation in
vitro. In functional assays using sub-optimal CD3 signaling, immobilized CD200 inhibited DETC proliferation and
cytokine secretion. Collectively, these results suggest that CD200:CD200R interactions may play a role in regu-
lating both LC and DETC in cutaneous immune reactions.
Key words: CD200/CD200-receptor/dendritic epidermal T cells/epidermis/Langerhans cells
J Invest Dermatol 125:1130 –1138, 2005
Skin represents the major physical barrier between the body
and the external environment and is supported by a robust
immunological defense system. Under steady-state condi-
tions, immunological components within the skin must be
maintained in a quiescent or resting state in order to prevent
autoimmunity. In recent years, it has come to be appreci-
ated that negative signals resulting from selective engage-
ment of inhibitory molecules play a vital role in the
prevention of unwanted autoimmune reactions (O’Garra
and Vieira, 2004; Prud’homme, 2004). CD200 (formerly
known as OX-2) is a transmembrane glycoprotein that
transmits a negative immunoregulatory signal to attenuate
inflammatory reactions and promote immune tolerance
(Hoek et al, 2000). We had previously reported that the
immunomodulatory molecule CD200 was necessary for in-
duction of tolerance to cutaneously applied hapten follow-
ing ultraviolet B (UVB) irradiation (Rosenblum et al, 2004a).
Furthermore, male (H–Y disparate) skin grafts from CD200-
deficient donors were rejected in accelerated fashion by
syngeneic CD200þ female hosts, suggesting a role for
CD200 in inhibition of graft rejection (Rosenblum et al,
2004b). In mouse skin, CD200 is preferentially expressed on
keratinocytes (KC) comprising the outer root sheath (ORS)
of the hair follicle (HF) (Rosenblum et al, 2004b). When
CD200-deficient skin grafts are placed on gender-matched
syngeneic recipients, they develop significant perifollicular
and intrafollicular inflammation that ultimately leads to com-
plete and permanent destruction of HF within the graft (alo-
pecia), but not to graft rejection (Rosenblum et al, 2004b).
Collectively, these findings led us to propose that CD200
plays a role in regulating immune responses in the skin,
including tolerance to HF-associated autoantigens.
CD200 mediates its effects by signaling through CD200-
receptor (CD200R). Like CD200, CD200R is a type I trans-
membrane glycoprotein with two extracellular immunoglob-
ulin-like domains (Wright et al, 2000). There is emerging
evidence that the CD200-receptor family is a paired inhibi-
tory/activating receptor system similar to that of other re-
ceptor Ig-like (e.g., FcR, PIR, etc) and type II lectin-like (e.g.,
NKG2 and Ly49) receptor families (Taylor et al, 2000).
CD200R was originally described as the sole receptor for
CD200, but later studies revealed three homologues that
were named CD200RLc, CD200RLb, and CD200RLa (Wright
et al, 2003). These homologues were subsequently recloned,
resequenced, and renamed CD200R2, CD200R3, and
CD200R4, respectively (Gorczynski et al, 2004). The original
CD200R was designated CD200R1 (Gorczynski et al, 2004).
CD200R1 acts as an inhibitory receptor (Wright et al, 2000),
whereas the R2–R4 homologues appear to be activating re-
ceptors (Wright et al, 2003; Voehringer et al, 2004). CD200-
mediated inhibition or activation of CD200 receptor cells may
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depend upon differential signaling through the various iso-
forms. Elucidation of CD200R expression patterns is critical
to an understanding of how CD200–CD200R interactions
might influence skin immune response.
Unlike CD200, which is found on a variety of cell types
(e.g., trophoblasts, neurons, endothelial cells, B lymph-
ocytes, and dendritic cells (DC), etc.), expression of
CD200R isoforms is restricted to leukocytes, with different
isoforms preferentially expressed on different populations.
Wright et al (2003) detected varying levels of CD200R1, R3,
and R4 on macrophages, DC, basophils, mast cells, and
polarized Th2 cells. CD200R1 was preferentially expressed
on bone marrow-derived macrophages, whereas the high-
est expression of CD200R3 and R4 was on basophils and
mast cells.
The two major leukocyte populations found in murine
epidermis are Langerhans cells (LC) and dendritic epidermal
T cells (DETC). LC are skin-resident antigen-presenting cells
(APC) that belong to the dendritic cell family. DETC are
phenotypically and functionally unique skin-resident gdþ T
cells (Boismenu et al, 1996). Both LC and DETC play im-
portant roles in cutaneous immune reactions and are found
in intimate association with epidermal KC, including those
of the ORS (Paus et al, 2003). KC influence both LC and
DETC function through secretion of cytokines, such as
granulocyte-macrophage colony-stimulating factor and
interleukin (IL)-7 (Matsue et al, 1993a, b). In addition, KC
influence the activity of LC and DETC through expression of
cell surface ligands such as CD40, CD80, intracellular cell
adhesion molecule (ICAM)-1, and B7-H1 (Fleming et al,
1993; Denfeld et al, 1996; Lonati et al, 1996; Mazanet and
Hughes, 2002). KC that express CD200 may affect cutane-
ous immune reactions through interactions with CD200Rþ
cells; however, to date, CD200R expression in the epidermis
has not been examined.
In this study, we characterized CD200R expression on
the major leukocyte populations in the murine epidermis.
We report that CD200R isoforms are differentially expressed
in LC and DETC. Freshly isolated LC preferentially ex-
pressed the inhibitory CD200R1 receptor on the cell surface
and showed a low activation state under steady-state con-
ditions. In contrast, LC from the epidermis of CD200-defi-
cient mice displayed a heightened state of activation. Fresh
DETC expressed low levels of CD200R1, but selectively
increased surface expression of CD200R1 upon ex vivo
activation. Ligation of CD200R on cells of the DETC line
7-17 with immobilized CD200.FLAG fusion protein led to
attenuated proliferation and cytokine secretion. These find-
ings support a regulatory role for CD200–CD200R in both
Langerhans and gdþ T cell populations of the skin.
Results
CD200R is expressed in the murine epidermis To deter-
mine if CD200R is expressed in the murine epidermis, we
performed quantitative real-time RT-PCR (qRT-PCR) for
CD200R1–4 on bulk epidermal cell (EC) suspensions from
B6 mice. B6 bone marrow was used as positive control.
As shown in Fig 1, CD200R1, R2, R3, and R4 were detected
in freshly isolated bulk EC. CD200R1 and CD200R2 con-
sistently showed the highest levels of expression, with
CD200R2 preferentially expressed in the epidermis com-
pared with bone marrow (Fig 1).
Murine epidermis contains three major cell populations:
(1) major histocompatibilty complex class II (MHCII)/gd
TCR (KC), (2) MHCIIþ /gd TCR (LC), and (3) MHCII/gd
TCRþ (DETC). To determine if CD200R isoforms were
differentially expressed in these cells, we purified the pop-
ulations by fluorescent-activated cell sorting (FACS) and
performed both CD200R-specific qRT-PCR and flow
cytometry analysis. The antibody used for flow cytometry
was OX-110, which specifically recognizes murine
CD200R1 (Wright et al, 2003 and Dr Neil Barclay, personal
communication). Cell surface CD200R1 expression was
observed on a small percentage of fresh DETC (Fig 2).
mRNA for CD200R1, R2, and R3 was detected in purified
DETC in three of three replicate experiments with
CD200R14R24R3, although the levels were not statisti-
cally different (Fig 2). Increased cell surface CD200R1 ex-
pression and increased CD200R1 mRNA expression were
observed on purified LC as compared with DETC (Fig 2).
Approximately 30% of purified LC expressed cell surface
CD200R1, and the median level of mRNA for CD200R1
were increased 15–75-fold over CD200R2 and CD200R3,
respectively, in this population (Fig 2). CD200R1, R2, and R3
(but not R4) mRNA expression was consistently detected in
MHCII/gd TCR KC, and a small percentage of these cells
expressed cell surface CD200R1 (Fig 2). Because the vast
majority of these cells are KC and because we did not de-
tect CD200R expression in several KC cell lines (data not
shown), we speculate that CD200R expression in our pu-
rified MHCII/gd TCR population may be from mast cell
and/or basophil contamination from the dermis or from
mast cell precursors known to be present in small numbers
within the epidermis (Kumamoto et al, 2003).
LC from CD200/ mice are at a heightened state of
activation CD200–CD200R interactions have been shown
to regulate myeloid cell activation in various tissues (Hoek
et al, 2000). Because CD200R1 is an inhibitory receptor
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Figure1
CD200-receptor (CD200R) is expressed in murine epidermis.
CD200R-specific quantitative real-time RT-PCR (qRT-PCR) was per-
formed on epidermal cell suspensions or bone marrow isolated from B6
mice. Results represent pooled data from two of three replicate
experiments. Denotes statistically significant values for each isoform
(p-valueo0.05) by Student’s t test. Although detected, the relative level
of CD200R4 mRNA was too low to show above the X-axis.
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(Zhang et al, 2004) and because LC constitutively express
cell surface CD200R1 (Fig 2), we set out to determine
whether CD200 signaling played a role in regulating the
resting activation state of murine LC. We prepared EC sus-
pensions from CD200/ mice and stained LC for various
cell surface activation markers. When compared to LC from
age/sex-matched wild-type (WT) B6 mice, LC from
CD200/ mice had significantly increased expression of
CD1d, CD11c, CD80, CD95 (FAS), CD178 (FASL), F4/80,
GR-1, and OX-40L (Fig 3). There was also significantly
higher expression of MHCII on LC from CD200/ mice as
compared with WT controls (CD200/ mean fluorescence
intensity (MFI)¼4527 vs WT MFI¼3878, p value¼0.003;
histograms not shown). Interestingly, there was no signifi-
cant difference in CD11b and CD86 expression between LC
from WT and CD200/ mice (Fig 3).
DETC increase CD200R1 expression with activation
DETC comprise approximately 1%–2% of total cells in the
murine epidermis. We detected low levels of CD200R1, R2,
and R3 expression on freshly isolated DETC (Fig 2). In some
experiments, the small numbers of CD200R1 expressing
cells showed greater forward light scatter, as measured by
flow cytometry, suggestive of activated cells (data not
shown). Therefore, we set out to determine if DETC in-
creased expression of CD200R upon activation. Epidermal
cells from B6 mice were cultured on anti-CD3 monoclonal
antibody (mAb)-coated plates in the presence of IL-2. At
various times, cells were harvested and gd-TCRþ DETC
were stained for cell surface CD200R1 and analyzed by flow
cytometry. A marked increase in CD200R1 expression was
observed by 48 h post-activation (data not shown), but
maximum expression was observed at 72 h (Fig 4a). To
determine expression of the other CD200R isoforms, DETC
were purified by FACS to X99% purity, cultured on anti-
CD3-coated plates in the presence of IL-2 and subjected
to CD200R-specific qRT-PCR. Consistent with cell surface
expression, DETC markedly increased CD200R1 mRNA
expression by 72 h after activation (Fig 4). In one of three
experiments, activated DETC also increased CD200R2 and
CD200R3 mRNA expression; however, these increases
were markedly diminished relative to increases in
CD200R1 expression (Fig 4b). CD200R4 mRNA was not
detected in either fresh or ex vivo activated DETC.
CD200–CD200R signaling inhibits DETC proliferation
and cytokine secretion Due to limitations in obtaining suf-
ficient numbers of DETC for functional studies, the DETC
cell line 7-17 was used to assess the functional role of
CD200–CD200R interactions. By several cellular and mo-
lecular criteria 7-17 cells have been shown to retain the
properties of freshly isolated DETC and are widely used in
studies addressing DETC function (Havran et al, 1991; Mat-
sue et al, 1993a–c; Edelbaum et al, 1995; Schuhmachers
et al, 1995; Takashima et al, 1995; Ono et al, 1996). To
determine if 7-17 cells expressed CD200R1, resting cells
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Figure 2
Characterization of CD200-receptor (CD200R) expression in epi-
dermal cell (EC) populations. CD200R1-specific flow cytometry and
CD200R1–R4 specific quantitative real-time RT-PCR (qRT-PCR) was
performed on bulk EC (not shown) and sorted EC, respectively. Tables
denote qRT-PCR values (arbitrary units normalized to 18S RNA in re-
spective populations) for CD200R isoforms (R1–R4) in sorted cells. The
median value from three to four replicate experiments is shown along
with the mean  SEM. Indicates that there is a statistically significant
difference (po0.05; Mann–Whitney U test) in mRNA expression within a
subpopulation as compared to CD200R1.
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Figure 3
Langerhans cells from CD200/ mice are maintained at a heightened state of activation. Four-color flow cytometry was performed on
epidermal cells (EC) isolated from wild-type (WT) B6 or CD200/ mice. Electronic gates were set on major histocompatibility complex class II
(MHCII)bright, 7-aminoactinomycin-D (7AAD) cells. Bold-line histograms represent staining with specific antibody, and light-line histograms rep-
resent staining with isotype-matched control antibody. Numeric values represent percent of cells staining positive and geometric mean fluorescence
intensity of positive cells. Boxes around marker names denote statistically significant differences between WT and CD200/ (four replicate
experiments; p-valueo0.05 by Student’s t test).
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(47 d post-Con A activation) were cultured on anti-CD3-
coated plates in the presence of IL-2. At various times, cells
were harvested for CD200R1-specific staining. Similar to
freshly isolated DETC, 7-17 DETC increased cell surface
expression of CD200R1 upon activation (Fig 5a). In contrast
to freshly isolated DETC, however, CD200R1 expression
was observed as early as 24 h after activation. By 72 h, a
population of presumably non-activated cells (decreased
forward light scatter) remained negative for CD200R1 ex-
pression (Fig 5a). To determine the expression pattern of all
four CD200R isoforms, we performed qRT-PCR on both
resting and anti-CD3 activated 7-17 cells. Consistent with
cell surface expression, 7-17 cells showed an increase in
CD200R1 mRNA upon activation (Fig 5b). The level of
CD200R1 mRNA increased an average of 8.8-fold by 72 h
post-activation over three experimental replicates. mRNA
for CD200R2 increased 1.8-fold by 72 h; however, this in-
crease was not statistically significant (Fig 5b). In contrast to
freshly isolated DETC, resting 7-17 cells expressed low lev-
els of CD200R4 mRNA, and upon activation, CD200R4
mRNA increased an average of 4.1-fold by 72 h. Also, in
contrast to freshly isolated DETC, mRNA for CD200R2 was
preferentially expressed in resting 7-17 cells (Fig 5b).
To determine if CD200 signaling influences DETC func-
tion in vitro, we activated 7-17 cells with sub-optimal anti-
CD3 mAb in the presence of immobilized CD200.FLAG fu-
sion protein and measured both proliferation and cytokine
secretion. 7-17 cells were cultured in microwell plates pre-
coated with a sub-optimal amount of anti-CD3 antibody
(predetermined concentration) and with CD200.FLAG fusion
protein in the absence of IL-2. As a negative control, cells
were cultured on plates pre-coated with both sub-optimal
anti-CD3 and bacterial alkaline phosphatase (BAP).FLAG
fusion protein. BAP.FLAG is approximately the same mo-
lecular weight as CD200.FLAG, was prepared in the same
manner, and should not bind to DETC. As a positive control,
7-17 cells were stimulated with an optimal amount of im-
mobilized anti-CD3 antibody. Immobilized CD200 signifi-
cantly inhibited the proliferative response of 7-17 cells to
sub-optimal CD3 stimulation (Fig 6). Between 3- and 11-fold
reductions in proliferation was observed when 7-17 DETC
were cultured on CD200-coated plates compared to BAP-
coated plates over three replicate experiments. In addition,
cytokine secretion was diminished when 7-17 cells were
activated in the presence of CD200 (Table I). A marked re-
duction in IL-2, tumor necrosis factor alpha (TNFa), and
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Figure 4
Dendritic epidermal T cells preferentially increase CD200-receptor
(CD200R)1 upon activation in vitro. (a) Epidermal cells were isolated
from B6 mice and cultured on anti-CD3-coated plates in the presence
of interleukin (IL)-2. At various times, cells were harvested and sub-
jected to CD200R1-specific flow cytometry. Cells are gated on gd-
TCRþ /7-aminoactinomycin-D (7AAD). Results are representative of
three replicate experiments. (b) gd-TCRþ /7AAD cells were purified by
fluorescent-activated cell sorting and cultured on anti-CD3-coated
plates in the presence of IL-2. At various times, cell were harvested and
subjected to CD200R-specific quantitative real-time RT-PCR. Results
represent pooled means from three replicate experiments. The level of
CD200R3 mRNA was too low to show above the X-axis, and no
CD200R4 mRNA was detected.
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Figure5
7-17 dendritic epidermal T cells increase CD200-receptor (CD200R)
expression upon activation in vitro. (a) Resting 7-17 cells (48 days
post-Con A activation) were cultured on anti-CD3-coated plates in the
presence of interleukin (IL)-2. At various times, cells were harvested and
subjected to CD200R1-specific flow cytometry. Quadrants were set
based on isotype control staining (not shown) and numeric values rep-
resent % cells staining positive/mean fluorescence intensity of entire
population. (b) Resting 7-17 cells were cultured on anti-CD3-coated plates
in the presence of IL-2. At various times, cells were harvested and sub-
jected to CD200R-specific quantitative real-time RT-PCR. Results repre-
sent pooled data from three replicate experiments. Denotes statistically
significant difference from time 0 (p-valueo0.05) by Student’s t test.
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interferon gamma (IFNg) was observed in CD200-treated
cells relative to BAP-treated cells in all three replicate ex-
periments. The results for IL-5 and IL-10 were inconsistent,
and IL-4, IL-6, IL-12 (p70), and monocyte chemotactic pro-
tein-1 were assayed but not consistently detected.
Discussion
A functional role for CD200–CD200R signaling in cutaneous
immune responses was suggested to us by four key find-
ings: (a) KC composing the ORS of HF constitutively ex-
pressed high levels of CD200 (Rosenblum et al, 2004b); (b)
CD200 protected gender-matched, syngeneic skin grafts
from inflammatory alopecia (Rosenblum et al, 2004b); (c)
CD200 attenuated the rejection of male skin grafts by
syngeneic female recipients (Rosenblum et al, 2004b); and
(d) CD200 was required for hapten-specific tolerance in a
cutaneous model of UVB-induced immune suppression
(Rosenblum et al, 2004a). Little is known about the expres-
sion of CD200R on cells of the epidermis. Herein, we show
that resting LC preferentially expressed CD200R1 and that
DETC preferentially increased CD200R1 expression upon
activation. Our data are consistent with the possibility that
CD200 may directly interact with CD200R1þ LC and/or
DETC to regulate immune reactions in the skin.
The activated phenotype for LC in the skin of CD200/
mice (Fig 3) is consistent with an earlier report from Hoek
et al (2000) that CD200/ mice have increased numbers of
activated myeloid-derived cells in their spleens, lymph
nodes, and central nervous system. Constitutively activat-
ed myeloid cells are thought to contribute to the increased
susceptibility of CD200/ mice to CNS inflammation, ex-
perimental autoimmune encephalomyelitis, and collagen-
induced arthritis (Hoek et al, 2000). Furthermore, viral
homologues of the CD200 gene have been linked to inhib-
itory signals that dampen the functions of tissue macro-
phages and CD200Rþ dendritic cells, thereby, contribute to
T cell anergy (e.g., Cameron et al, 2005).
Interaction between CD200 and the inhibitory CD200R1-
receptor may be important for maintaining LC in an
immature phenotype that is tolerogenic rather than
immunostimulatory. The maturation or activation state of
DC is known to influence their ability to stimulate or tolerize
T cells (Steinman et al, 2003), and immature LC have been
shown to play a role in silencing self-reactive T cells in
the steady state (von Bubnoff et al, 2004). We speculate
that alopecia previously described in syngeneic, gender-
matched skin grafts from CD200-deficient donors (Rosen-
blum et al, 2004b) may be due to a failure of cells within the
graft to regulate (tolerize) potentially autoreactive T cells
recruited to the inflammatory milieu of the graft by
chemokines. Heightened autoreactivity in the absence of
CD200–CD200R interaction is supported by in vitro studies
showing that CD11cþ DC isolated from CD200/ mice
induce autologous CD4þ T cells to secrete significantly
higher levels of IFNg and TNFa as compared with DC from
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Figure 6
CD200 signaling inhibits 7-17 dendritic epidermal T cells (DETC)
proliferation. 7-17 DETC were cultured on uncoated plates (no anti-
CD3 mAb) or plates coated with either optimal anti-CD3, sub-optimal
anti-CD3þ bacterial alkaline phosphatase (BAP).FLAG, or sub-optimal
anti-CD3þCD200.FLAG (625 ng per well) in the absence of interleukin
(IL)-2. Proliferation was measured at 88 h by [3H]-thymidine incorpo-
ration. Results are representative of 3 replicate experiments. Denotes
statistically significant from BAP.FLAG control (p-valueo0.05) by Stu-
dent’s t test.
Table I. CD200 signaling inhibits DETC cytokine secretiona
Cytokine
(pg per mL)
Experiment #1 Experiment #2 Experiment #3
Optimal
anti-CD3
Sub-optimal anti-CD3
Optimal
anti-CD3
Sub-optimal anti-CD3
Optimal
anti-CD3
Sub-optimal anti-CD3
BAP.
FLAG
CD200.
FLAG
BAP.
FLAG
CD200.
FLAG
BAP.
FLAG
CD200.
FLAG
IL-2 529 12.3 4.7 37.1 10.1 5.9 2234 1295 703
IL-5 19.3 1.5 3.0 144 149 124 165 155 o1
IL-10 17.9 18.7 25.2 21.9 14.1 18.7 22.7 21.1 7.8
TNFa 5587 2657 1610 7384 1888 974 9430 4616 2572
IFNg 38,267 8770 6056 36,766 12,563 7337 42,778 16,283 9534
a7-17 DETC were cultured on plates bound with sub-optimal immobilized anti-CD3 mAb and either BAP.FLAG or CD200.FLAG fusion protein in the
absence of exogenous IL-2. Optimal anti-CD3 mAb was used as a positive control. Supernatants were harvested at 72 h and analyzed for various
cytokines by cytometric bead array. IL-4, IL-6, IL-12 (p70), and MCP-1 were not consistently detected. Limit of detection was approximately 1.5 pg per
mL. Values shown are pg per mL. Individual results from three replicate experiments are shown.
DETC, dendritic epidermal T cells; mAb, monoclonal antibody; BAP, bacterial alkaline phosphatase; IL, interleukin; TNFa, tumor necrosis factor alpha;
IFNg, interferon gamma.
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CD200þ /þ mice (Rosenblum et al, 2004a). Furthermore,
since LC are considered to be the central mediators of
UVB-induced tolerance (Aubin, 2003), increased resistance
of activated LC in CD200/ mice to the immunosuppres-
sive effects of UVB irradiation may have contributed to the
lack of UVB-induced tolerance to hapten observed in such
mice (Rosenblum et al, 2004a).
The effector mechanism(s) by which ligation of CD200R
leads to diminished immune reactivity in our models of alo-
pecia and UVB-induced hapten-specific tolerance has not
been determined. Recent data from others, however, have
shown that ligation of CD200R on plasmacytoid DC is
a potent stimulus for production of indoleamine-2,3-
dioxygenase (IDO) (Fallarino et al, 2004). IDO promotes
peripheral T cell tolerance through a mechanism involving
tryptophan catabolism (Mellor and Munn, 2004). Since hu-
man LC can be induced to produce IDO (von Bubnoff et al,
2004), it is possible that CD200R interaction with CD200
acts to maintain IDO expression in LC and contributes to an
epidermal milieu that is less favorable to recruitment and
activation of potentially auto-, allo-, or hapten-reactive T
cells. Based on data reported here, the inhibitory CD200R1
isoform is the most likely receptor on LC for ligation by
CD200þ KC in such settings.
CD200R1 lacks a classical inhibitory (ITIM-like) motif, but
it has a 67AA cytoplasmic tail with a conserved phospho-
tyrosine within an NPXY motif (Zhang et al, 2004). This motif
is a well-characterized target for signal adaptor proteins
containing phosphotyrosine-binding (PTB) domains (Kavan-
augh and Williams, 1994). Upon binding to CD200,
CD200R1 is phosphorylated and binds the PTB-containing
inhibitory adaptor proteins Dok 1 and Dok 2, which lead
downstream to inhibition of the Ras/MAPK pathways
(Zhang et al, 2004). In mast cells, this results in attenuation
of degranulation and cytokine secretion (Zhang et al, 2004).
In contrast to CD200R1, homologues R2, R3, and R4 ap-
pear to be activating receptors. They have short 15AA cy-
toplasmic tails with no known signaling motifs, but highly
related transmembrane domains with a conserved positive-
ly charged lysine residue (Wright et al, 2003; Gorczynski
et al, 2004). This motif is involved in the recruitment of ac-
tivating transmembrane adaptor proteins such as CD3z,
DAP-12, and the g-chain of Fc receptors (Lanier et al, 1998).
CD200R2–R4 associate with DAP12, and R3 and R4 require
DAP12 for stable surface expression (Voehringer et al,
2004). Cross-linking of CD200R4 is a potent stimulus for
mast cell degranulation (Zhang et al, 2004). A fifth member
of the CD200R-family (CD200R5) has been identified by
BLAST search, but this isoform has not been detected in
murine tissues or cell lines and remains to be fully charac-
terized (Voehringer et al, 2004).
Whether CD200–CD200R interactions play a direct
role in the regulation of T cell activity has been controver-
sial because of initial difficulties in detecting CD200R on
T cells (Wright et al, 2000; Wright et al, 2003). CD200
was originally described as a T cell costimulatory molecule
(Borriello et al, 1997), and antibodies to CD200R2 (but
not R1) augment the induction of foxp3-expressing regula-
tory T cells from anti-CD3/CD28 activated thymocytes
(Gorczynsky et al, 2005). Earlier, Gorczynsky et al (2000)
reported that gd T cells derived from the spleen bind CD200.
DETC are a unique population of gd T cells that play a
regulatory role in diverse immune reactions involving the
skin, including autoimmunity, allergic contact dermatitis,
cutaneous graft-vs-host disease, tumor immunity, and
would healing (Boismenu et al, 1996; Shiohara et al, 1996;
Girardi et al, 2001, 2002; Jameson et al, 2002). Here, we
show for the first time that DETC express CD200R. Al-
though few fresh DETC were positive for surface expres-
sion of the inhibitory CD200R1-receptor (  1%, Fig 2),
they preferentially increased expression of CD200R1 over
time after activation, peaking at 72 h (Fig 4). In functional
studies using the DETC cell line 7-17, ligation of CD200R
by immobilized CD200.FLAG fusion protein in the presence
of sub-optimal anti-CD3 mAb resulted in decreased prolif-
eration and diminished cytokine secretion (Fig 6 and Table
I). DETC recognize and respond to antigens expressed
on KC (Havran et al, 1991) and are found in close proximity
to the ORS (Paus et al, 2003). Our data suggest that CD200
on KC may attenuate or modulate DETC responses follow-
ing activation and upregulation of CD200R1. In an attempt
to directly test this hypothesis in vivo, we performed
wounding experiments using a model known to induce
DETC activation (Jameson et al, 2002) and compared DETC
from WT and CD200/ mice at various times post-wound-
ing. Subjectively, there was accelerated healing of wounds
in CD200-deficient mice, but we have not observed any
consistent differences in DETC number and activation state
between the two groups (M. Rosenblum, unpublished data).
Difficulties in obtaining adequate numbers of DETC post-
wounding, however, has hampered these experiments and
their interpretation. We are currently exploring other models
to test this hypothesis.
There are conflicting reports about whether CD200 can
act as a ligand for all of the CD200R isoforms. Gorczynski et
al (2004) claim that CD200 binds to all four isoforms, but
Wright et al (2003), using soluble CD200 and cells
transfected with plasmids for CD200R1, R3, and R4,
concluded that CD200R1 was the only receptor to bind
CD200. Their conclusion is bolstered by recent data
showing negligible binding of a CD200-Fc fusion protein
to the activating receptors (i.e., CD200R2-R4) by surface
plasmon resonance (Hatherley et al, 2005). These investi-
gators speculate that the activating isoforms of CD200
may have evolved to interact with components of bacteria
or viruses, whereas the inhibitory CD200R1 receptor binds
to an endogenous host protein, CD200 (Hatherley et al,
2005). Although the functional and biological significance of
the activating CD200R isoforms are currently unknown,
there is consensus that CD200R1 acts as an immunoinhi-
bitory receptor upon binding CD200. Our findings with
epidermal leukocytes are consistent with this since (a) LC
showed heightened activation in the absence of CD200
(Fig 3) and (b) ligation of CD200R with immobilized CD200.
FLAG led to impaired proliferation and cytokine secretion by
7–17 DETC cells (Fig 6 and Table I). Inhibition was the
dominant functional outcome of CD200 ligation with DETC
(Fig 5b) even though 7–17 cells expressed mRNA for all
CD200R isoforms (R2 4R14R44R3, Fig 5b). The partial
inhibition of 7–17 cells may reflect heterogeneity in expres-
sion of CD200R1 by cultured as compared with primary
DETC (Figs 5a vs 4a).
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In summary, the results presented herein further our un-
derstanding of how CD200 might be involved in the regu-
lation of immune responses in cutaneous tissues. Our
previous work characterizing the CD200 ligand in the skin,
taken together with the knowledge that LC and DETC (as
reported here) as well as mast cells (as reported by others,
e.g., Zhang et al, 2004; Cherwinski et al, 2005) express
CD200R and are capable of being regulated by CD200–
CD200R interactions, provide new insight into a novel path-
way of immune regulation in the skin. As in other tissues, this
pathway may be important for maintaining a quiescent (ba-
sal) state and tissue-specific tolerance to potential autoan-
tigens (such as those associated with HF) under steady-
state conditions. Disruption of this pathway may contribute
to the pathogenesis of autoimmune disease(s) in the skin.
Materials and Methods
Mice C57BL/6 mice (B6) were purchased from The Jackson Lab-
oratory (Bar Harbor, Maine). CD200/ mice (derived in the B6
background (Hoek et al, 2000) were provided by Dr Jonathan Se-
dgwick (DNAX Research Institute, Palo Alto, California)). All mice
were housed in the Medical College of Wisconsin’s Biomedical
Resource Center, which is accredited by the American Association
for the Accreditation of Laboratory Animal Care. All animal studies
were conducted under a protocol approved by the Institutional
Animal Care and Use Committee.
EC preparations Adult ear skin was excised from B6 mice and
EC were isolated as previously described (Tamaki et al, 1979).
Briefly, skin was separated from the cartilage plate and floated
on 0.5% trypsin (GIBCO BRL, Grand Island, New York) in phos-
phate-buffered saline (PBS) at 371C for 45 min. Epidermal sheets
were peeled from the dermis, re-suspended in 0.05% DNAase
(Sigma, St Louis, Missouri) in PBS containing 10% fetal bovine
serum (FBS). Single-cell suspension was obtained by vigorous
passage through a 60 cm3 syringe. For flow cytometry, freshly
isolated EC were washed 1  in cold PBS and 4  105 cells were
stained for 30 min at 41C with the following: Alexa Fluor-647 (Mo-
lecular Probes, Eugene, Oregon) conjugated anti-mCD200R1 an-
tibody (OX-110); Alexa Fluor-647-conjugated rat IgG isotype
control (R35–95); PE anti-mouse gd TCR (GL3); FITC anti-I-Ab
(KH74); 7-aminoactinomycin-D (7AAD) (CalBiochem, La Jolla, Cal-
ifornia). All antibodies were from Pharmingen (San Diego, Califor-
nia) except OX-110, which was generously provided by Neil A.
Barclay (University of Oxford, UK). OX-110 and R35–95 mAb were
conjugated to Alexa Fluor 647 according to manufacturer’s proto-
col. Cells were washed twice in cold PBS and analyzed by flow
cytometry on a Becton Dickinson (BD) (San Jose, California) FAC-
Scan flow cytometer.
For phenotypic and RT-PCR analysis, purified epidermal leu-
kocyte populations were obtained by FACS. Epidermal cell sus-
pensions were stained with PE anti-mouse gd TCR, FITC anti-I-Ab,
and 7AAD. gd TCRþ /I-A/7AAD (DETC), gd TCR/I-Aþ /7AAD
(LC), and gd TCR/I-A/7AAD (KC) cells were sorted to X99%
purity with a BD FACS DiVa with BD TurboSort Plus options.
Freshly isolated LC were immunostained with antibodies specific
for the following cell surface markers: CD1d, CD11b, CD11c,
CD80, CD86, FAS, FAS-L, and Gr-1 (all from BD Biosciences, San
Jose, California) as well as F4/80 (Serotec, Raleigh, North Carolina)
and OX40L (eBioscience, San Diego, California).
For activation experiments, purified DETC were cultured in 96-
well plates pre-coated with 10 mg per mL anti-CD3 (145–2C11;
Pharmingen) at 371C in 5% CO2 for up to 72 h. Culture media was
RPMI with 10% heat-inactivated FBS supplemented with 50 mM
2-mercaptoethanol (Sigma), HEPES buffer (25 mM), sodium pyruv-
ate (1 mM), penicillin (100 U per mL), streptomycin (100 mg per mL),
L-glutamine (2 mM), 100 mM non-essential amino acids, and 20 U
per mL recombinant human IL-2. All components were obtained
from GIBCO BRL unless otherwise specified.
qRT-PCR Epidermal cell suspensions were sorted into purified
DETC, LC, and KC populations as described above. Cells were
harvested, and total RNA was extracted with TRIzol according to
manufacturer’s instructions (Life Technologies, Rockville, Mary-
land). RNA was quantified, and equal amounts (  1 mg) were re-
verse transcribed into cDNA with oligo(dT) primers using
Thermoscript RT-PCR systems (GIBCO BRL) according to manu-
facturer’s instructions. To increase the sensitivity of detection in
experiments were DETC were sorted and subsequently activated,
10 ng of total RNA was amplified prior to qRT-PCR using the Ova-
tion RNA amplification system according to manufacturer’s proto-
col (NuGen Technologies, San Carlos, California). qRT-PCR was
performed using the following CD200R-specific primer and
probe combinations: CD200R1 forward—50tacaaaggctctgctctgct30,
CD200R1 reverse—50aagcagctggtttcattggt30, CD200R1 probe—
50agaggcctgccatcctgcac30; CD200R2 forward—50caaccaaaggcta-
cacatgg30, CD200R2 reverse—50agggtttctccttccactga30, CD200R2
probe—50tggatggccttgttgggca30; CD200R3 forward—50tggtg-
cctgagtcaagttgt30, CD200R3 reverse—50cccactccatcagggaag30,
CD200R3 probe—50cgggaggagatcccaccgg30; CD200R4 for-
ward—50tgtgtctgttgtgtcctgctt30, CD200R4 reverse—50tggaaga-
aagcaaatcctacg30, and CD200R4 probe—50cccccgttccttgctgacca30.
As control, pre-formulated 18S rRNA Gene Expression Assay
systems was utilized according to manufacturer’s protocol
(Applied Biosystems, Foster City, California). Due to allelic varia-
tion in CD200R isoform sequences between B6 and AKR mice (M.
D. Rosenblum, unpublished data), the following primers were used
for qRT-PCR of 7-17 cells (derived from AKR mice): CD200R1
forward—50cacctgaccacagtcctgaa30, CD200R1 reverse—50tgcag-
gacacatcagacaca30, CD200R2 forward—50cagacaccaaacccag-
acac30, CD200R2 reverse—50gaccaagggtttctccttcc30, CD200R3
forward—50tggtgcctgagtcaagttgt30, CD200R3 reverse—50cccac-
tccatcagggaag30, CD200R4 forward—50ctgctgcacagatctcttgg30,
CD200R4 reverse—50gacagcagggacaggtaagc30. As control, b-
actin expression (foward—50gagtcctgtggcatccacg30 and re-
verse—50ctaggagcatttgcggtggac30) was compared to CD200R
isoform expression using SYBR Green detection reagent accord-
ing to manufacturer’s protocol (Stratagene, La Jolla, California). All
qRT-PCR reactions were carried out in an Opticon-2 Continuous
Fluorescence Detector (MJ Research, Boston, Massachusetts).
Data were analyzed using the comparative Ct method (Applied
Biosystems).
Construction of CD200.FLAG and BAP.FLAG fusion pro-
teins Unless noted otherwise, all procedures were done accord-
ing to the instructions provided by the annotated manufacturer.
Total RNA was extracted from murine splenocytes using TRIzol.
RNA was reverse transcribed into cDNA with oligo(dT) primers us-
ing Thermoscript RT-PCR systems. The following primers specific
for the extracellular domain of murine CD200, containing HindIII
and BamH1 restriction sites were synthesized (Invitrogen, Grand
Island, New York): 50cccaagcttatgggcagtctggtattcagg30; 50cgcgg-
atcctcctttgtccagactctgctt30. Amplified products were then cloned
and sequenced utilizing the pCR2.1-TOPO cloning vector and the
TOPO TA Cloning kit (Invitrogen). Inserts were cloned into the
p3XFLAG-CMV-13 expression vector utilizing HindIII and BamH1
restriction enzymes (Sigma). This vector is designed for the stable
expression and secretion of C-terminal-linked 3xFLAG fusion pro-
teins. As control, FLAG taggedBAP fusion protein vector (pFLAG-
CMV-3-BAP) was purchased from Sigma. Chinese hamster ovary
cells (CHO) were nucleofected with either CD200.FLAG or
BAP.FLAG vectors (Amaxa Biosystems, Koeln, Germany). Nu-
cleofection was optimized using Amaxa’s Cell Line Optimization
Nucleofector Kit. Culture supernatants were harvested 5–7 d later
and filtered concentrated using YM-10 Centriplus centrifugal filter
devices (Millipore, Bedford, Massachusetts). Concentrated fusion
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protein was assayed for purity by western blot using anti-FLAG M2
antibody (Sigma). Fusion protein was quantified by densitometry
on western blots with known concentrations of 3xFLAG-BAP pro-
tein as standard (Sigma) using Alpha Imager 2200 v5.5 software on
an Alpha Imager 2200 (Alpha Innotech, San Leandro, California).
DETC functional assays The DETC cell line, 7-17, was kindly
provided by Dr Wendy Havran (The Scripps Research Institute,
La Jolla, California). These cells were originally isolated by FACS
of epidermal cell preparations from AKR mice (Kuziel et al,
1987). Cells were maintained in complete RPMI (with IL-2) and
stimulated every 21 days with 5 mg per mL Con A. Only resting 7-17
DETC (i.e., cells stimulated with Con A47 d previously) were
used in functional assays. 5  105 cells were cultured in 96-
well plates bound with 0.5 mg per mL anti-CD3 mAb (predeter-
mined sub-optimal concentration) or 2 mg per mL anti-CD3 (pre-
determined optimal concentration) and 10 mg per mL anti-FLAG
M2 antibody. Approximately 30 min before plating cells, 650 ng
of CD200.FLAG or BAP.FLAG was added to anti-CD3, anti-
FLAG coated plates. Cells were cultured in complete RPMI (with-
out IL-2) at 371C in 5% CO2. After 72 h, cytokine levels were
measured from culture supernatants using cytometric bead arrays
(CBA; BD Biosciences) according to the manufacturer’s pro-
tocol. To measure proliferation, cells were pulsed with 1 mCi per
mL [3H]-thymidine at 72 h and assayed for thymidine uptake 16 h
later.
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